New data show superiority of abbott's triclip™ device compared to medical therapy for tricuspid regurgitation

Late-breaking data presented at american college of cardiology scientific sessions (acc.23) and simultaneously published in the new england journal of medicine demonstrate triclip was superior to medical therapy with significant improvements in quality of life and tricuspid regurgitation (tr) findings show triclip, an investigational device in the u.s. to treat a leaky tricuspid valve, demonstrated safety and met the primary endpoint abbott park, ill., march 4, 2023 /prnewswire/ -- abbott (nyse: abt) today announced late-breaking data for the triclip™ transcatheter edge-to-edge repair (teer) system, a first-of-its-kind minimally invasive device designed specifically for tricuspid heart valve repair.
ABT Ratings Summary
ABT Quant Ranking